Abstract
Protein prenylation involves the addition of a farnesyl (C15) or geranylgeranyl (C20) isoprenoid moiety onto the C-terminus of approximately 2 % of all mammalian proteins. This hydrophobic modification serves to direct membrane association of the protein. Due to the finding that the oncogenic protein Ras is naturally prenylated, several researchers have developed inhibitors of the prenyltransferase enzymes as cancer therapeutics. Despite numerous studies on the enzymology of prenylation in vitro, many questions remain about the process of prenylation in living cells. Using a combination of flow cytometry and confocal microscopy, we have shown that synthetic fluorescently labeled prenylated peptides enter a variety of different cell types. Additionally, using capillary electrophoresis we have shown that these peptides can be detected in minute quantities from lysates of cells treated with these peptides. This method will allow for further study of the enzymology of protein prenylation in living cells.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC (1991) Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci U S A 88:9668–9670
Benetka W, Koranda M, Eisenhaber F (2006) Protein prenylation: an (almost) comprehensive overview on discovery history, enzymology, and significance in physiology and disease. Monatsh Chem 137:1241–1281
Casey PJ (1992) Biochemistry of protein prenylation. J Lipid Res 33:1731–1740
Clarke S (1992) Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61:355–386
Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241–269
Agrawal AG, Somani RR (2009) Farnesyltransferase inhibitor as anticancer agent. Mini-Rev Med Chem 9:638–652
Sousa SF, Fernandes PA, Ramos MJ (2008) Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 15:1478–1492
Blum R, Kloog Y (2005) Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updates 8:369–380
Karp JE, Lancet JE (2007) Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Invest 25:484–494
Zhu K, Hamilton AD, Sebti SM (2003) Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs 4:1428–1435
Cole SL, Vassar R (2006) Isoprenoids and Alzheimer’s disease: a complex relationship. Neurobiol Dis 22:209–222
Florent-Bechard S, Desbene C, Garcia P, Allouche A, Youssef I, Escanye M-C et al (2009) The essential role of lipids in Alzheimer’s disease. Biochimie 91:804–809
Ostrowski SM, Wilkinson BL, Golde TE, Landreth G (2007) Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 282:26832–26844
Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Muller WE et al (2009) Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis 35:251–257
Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y et al (2009) Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson’s disease. Proc Natl Acad Sci U S A 106:4635–4640
Ochocki JD, Igbavboa U, Wood WG, Wattenberg EV, Distefano MD (2010) Enlarging the scope of cell-penetrating prenylated peptides to include farnesylated CAAX box sequences and diverse cell types. Chem Biol Drug Des 76:107–115
Wollack JW, Zeliadt NA, Mullen DG, Amundson G, Geier S, Falkum S et al (2009) Multifunctional prenylated peptides for live cell analysis. J Am Chem Soc 131:7293–7303
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ochocki, J.D., Igbavboa, U., Wood, W.G., Arriaga, E.A., Wattenberg, E.V., Distefano, M.D. (2014). Evaluation of Prenylated Peptides for Use in Cellular Imaging and Biochemical Analysis. In: Nixon, A. (eds) Therapeutic Peptides. Methods in Molecular Biology, vol 1088. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-673-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-62703-673-3_14
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-672-6
Online ISBN: 978-1-62703-673-3
eBook Packages: Springer Protocols